Koers Shanghai Pharmaceuticals Holding Co., Ltd Other OTC
Aandelen
SHPMY
US81943R1005
Farmaceutische producten
Omzet 2024 * | 288 mld. 39,87 mld. 36,69 mld. | Omzet 2025 * | 317 mld. 43,81 mld. 40,31 mld. | Marktkapitalisatie | 62,19 mld. 8,6 mld. 7,91 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,83 mld. 668 mln. 614 mln. | Nettowinst (verlies) 2025 * | 5,84 mld. 807 mln. 743 mln. | EV/omzet 2024 * | 0,26 x |
Nettoschuld 2024 * | 13,27 mld. 1,83 mld. 1,69 mld. | Nettoschuld 2025 * | 19,41 mld. 2,68 mld. 2,47 mld. | EV/omzet 2025 * | 0,26 x |
K/w-verhouding 2024 * |
12,7
x | K/w-verhouding 2025 * |
11,4
x | Werknemers | - |
Dividendrendement 2024 * |
3,04% | Dividendrendement 2025 * |
3,44% | Vrij verhandelbaar | 38,5% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Bo Shen
PSD | President | 51 | 05-06-13 |
Ye Lu
IRC | Investor Relations Contact | 35 | 01-01-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Bo Shen
PSD | President | 51 | 05-06-13 |
Yong Zhong Li
PSD | President | 54 | 27-06-19 |
Manson Fok
BRD | Director/Board Member | 67 | 27-06-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,82% | 73,31 mld. | |
-2,32% | 23,98 mld. | |
+4,89% | 8,8 mld. | |
-19,56% | 8,07 mld. | |
+14,47% | 5,26 mld. | |
-0,93% | 4,16 mld. | |
+12,13% | 4,14 mld. | |
-2,96% | 3,88 mld. | |
+24,77% | 3,72 mld. |